<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of chronic pain in advanced chronic kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of chronic pain in advanced chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of chronic pain in advanced chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara N Davison, MD, MHSc, FRCP(C)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1838178710"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pain is one of the most common and distressing symptoms among patients with chronic kidney disease (CKD) [<a href="#rid1">1</a>]. The prevalence of pain has been associated with substantially lower health-related quality of life and greater psychosocial distress, insomnia, and depressive symptoms [<a href="#rid2">2-9</a>]. Among hemodialysis patients, severe pain is also independently associated with shortened or missed hemodialysis treatments and increased health services utilization, such as emergency department visits and hospitalizations [<a href="#rid10">10</a>].</p><p>Many analgesics that are typically used in the non-CKD population should not be used among patients with advanced CKD (ie, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>; including those on dialysis). This topic reviews the epidemiology, assessment of pain, and management of pain among patients with advanced CKD.</p><p>The evaluation and management of pain in the general adult population and among patients with mild to moderate CKD (ie, eGFR ≥30 mL/min/1.73 m<sup>2</sup>) is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116196.html" rel="external">"Evaluation of chronic non-cancer pain in adults"</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H624275934"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pain is more prevalent among CKD patients than in the general population. Over 60 percent of hemodialysis patients describe moderate or severe chronic pain [<a href="#rid1">1,11</a>]. By contrast, according to a national survey, approximately 20 percent of adults in the United States (both with and without CKD) have reported chronic pain, and approximately 7 percent have high-impact chronic pain (ie, pain that results in limitations in major life domains) [<a href="#rid12">12</a>].</p><p>Most studies of CKD patients have included only hemodialysis patients [<a href="#rid1">1</a>]. A few small studies have suggested that pain is as common among peritoneal dialysis patients and stage 5 CKD patients who are not on dialysis as among chronic hemodialysis patients [<a href="#rid1">1</a>].</p><p>Very few studies have reported the prevalence of pain among patients with nondialysis CKD. A single, small study of 130 nondialysis CKD patients with varying severity of CKD suggested that the prevalence of pain was similar (64 to 75 percent) among all levels of CKD patients [<a href="#rid13">13</a>]. However, it is not clear that patients included in this study are representative of CKD patients in the general population, since all patients in this study were drawn from a CKD clinic; many individuals with mild declines in estimated glomerular filtration rate (eGFR; ie, 60 to 89 mL/min/1.73 m<sup>2</sup>) are not followed in CKD clinics.</p><p>Most studies in CKD patients show no association of chronic pain with sex, age, race, or ethnicity [<a href="#rid2">2-8,11,14,15</a>].</p><p class="headingAnchor" id="H624275946"><span class="h1">ASSESSMENT OF PAIN</span></p><p class="headingAnchor" id="H513528797"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Both dialysis and nondialysis CKD patients should be screened routinely for the presence of pain since pain is highly prevalent, is associated with diminished quality of life and other symptoms, and is poorly recognized and quantified by care providers [<a href="#rid2">2-10,16,17</a>]. The reason for screening is that pain may be treated successfully if it is identified and sufficiently characterized by the care provider. In addition, the routine assessment of pain often provides an opportunity for difficult discussions about appropriate palliative- and supportive-care options.</p><p>There are at least eight validated symptom assessment tools designed to identify CKD patients with chronic pain  (<a class="graphic graphic_table graphicRef100576" href="/z/d/graphic/100576.html" rel="external">table 1</a>) [<a href="#rid2">2,3,18-25</a>]. Tools such as the Edmonton Symptom Assessment System Revised: Renal (ESAS-r:Renal) [<a href="#rid2">2,3,26</a>] and Palliative Care Outcome Scale-Renal (POS-renal) are particularly useful for routine clinical screening for pain in kidney programs because they are short, relatively simple to complete by the patient, and require minimal facilitation from staff [<a href="#rid18">18,19</a>]. For cognitively impaired or nonverbal patients, specialized pain assessment tools like the Abbey Pain Scale should be used [<a href="#rid27">27</a>].</p><p>The use of these global symptom screening tools also allows for the assessment of other bothersome symptoms that often accompany pain, such as depression, anxiety, itch, nausea and vomiting, anorexia, shortness of breath, and poor sleep.</p><p>We use the ESAS-r:Renal to screen CKD patients for pain  (<a class="graphic graphic_form graphicRef104715" href="/z/d/graphic/104715.html" rel="external">form 1</a>). We integrate routine screening of hemodialysis patients during monthly assessments. We screen home dialysis patients and predialysis advanced CKD patients quarterly at the time of clinic visits.</p><p>Once pain is identified, it should be further evaluated as to cause. Depending on the cause of pain, a specific intervention or pharmacologic treatment may be indicated. As an example, the patient with vascular steal syndrome may require a surgical intervention. (See  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications", section on 'Access flow-related problems'</a>.)</p><p class="headingAnchor" id="H513528803"><span class="h2">Causes</span><span class="headingEndMark"> — </span>CKD patients are vulnerable to all the causes of pain that affect the general population. In addition, CKD patients may experience pain related to their primary kidney disease (eg, polycystic kidney disease), comorbid conditions (eg, diabetic neuropathy or peripheral vascular disease), or sequelae of CKD (such as calcific uremic arteriolopathy [calciphylaxis], bone pain from renal osteodystrophy, and dialysis-related amyloid arthropathy). Most studies have not shown an association of pain with the biochemical derangements common in CKD [<a href="#rid2">2-8,11,14,15</a>]. However, a single but large study of 1469 patients showed that, among dialysis patients, disturbed metabolism of calcium, phosphate, and parathyroid hormone is associated with more muscle, joint, and bone pain [<a href="#rid28">28</a>].</p><p>Pain may also be directly or indirectly related to dialysis. Painful conditions may be related to the dialysis access. As examples, arteriovenous fistulas can lead to painful ischemic neuropathies, and tunneled catheters may result in painful, chronic infections such as osteomyelitis and discitis. (See  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications", section on 'Access flow-related problems'</a>.)</p><p>Pain may also be directly related to the dialysis treatment; hemodialysis patients often experience recurrent cramps or headaches during their dialysis treatments [<a href="#rid29">29</a>], and peritoneal dialysis patients may have pain due to abdominal distension, recurrent peritonitis, and lower back strain [<a href="#rid29">29</a>].</p><p>Pain is generally classified as either nociceptive or neuropathic. Nociceptive pain is usually due to tissue injury. Causes of nociceptive pain common among advanced CKD patients include (but are not limited to) osteoarthritis, renal osteodystrophy, dialysis-related amyloid arthropathy, and kidney or liver capsule distension from autosomal dominant polycystic kidney disease (ADPKD). All can cause mild, moderate, or severe pain. (See <a class="local">'Nociceptive pain'</a> below.)</p><p>Neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system (see <a class="local">'Neuropathic pain'</a> below). Common examples of neuropathic pain among patients with CKD include but are not limited to diabetic neuropathy, phantom limb pain, and carpel tunnel syndrome.</p><p>Among CKD patients, the pain is often mixed nociceptive/neuropathic in nature. (See <a class="local">'Mixed nociceptive and neuropathic pain'</a> below.)</p><p class="headingAnchor" id="H1239486792"><span class="h1">TREATMENT OVERVIEW</span><span class="headingEndMark"> — </span>In the general adult population, treatment options for chronic pain fall into six major categories: pharmacologic, physical medicine, behavioral medicine, neuromodulation, interventional, and surgical approaches. Optimal patient outcomes often result from multiple approaches utilized in concert and coordinated by a multidisciplinary team that includes pain specialists. Medication is not the sole focus of treatment but is used when nonpharmacologic interventions have been insufficient to adequately control pain. Medication is best used in conjunction with other treatment modalities to meet treatment goals [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H513529680"><span class="h2">Nonpharmacologic treatment</span><span class="headingEndMark"> — </span>Nonpharmacologic modalities are generally the same among CKD patients as in the general population and are discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults", section on 'Nonpharmacologic therapies'</a>). However, frailty or general disability may prevent some patients from benefiting fully from physical interventions. In addition, behavioral approaches such as cognitive-behavioral therapy (CBT) may be challenging and possibly less accessible for some CKD patients, especially those already on dialysis, because of the time and cognitive ability required. Regardless, where available, these modalities should be tried as first-line therapy.</p><p class="headingAnchor" id="H3890441370"><span class="h2">Pharmacologic treatment of mild to moderate CKD (eGFR ≥30 mL/min/1.73 m2)</span><span class="headingEndMark"> — </span>With the exception of nonsteroidal antiinflammatory drugs (NSAIDs), the pharmacologic treatment of chronic pain in patients with mild to moderate CKD is similar to the general population without CKD. However, NSAIDs should typically be avoided. Adverse effects of NSAIDs include a reduction in estimated glomerular filtration rate (eGFR) that can be severe and irreversible, sodium and water retention that may aggravate hypertension, and hyperkalemia. These and other adverse effects of NSAIDs are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a> and  <a class="medical medical_review" href="/z/d/html/7176.html" rel="external">"Epidemiology and pathogenesis of analgesic-related chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults", section on 'NSAID use and comorbidities'</a> and  <a class="medical medical_review" href="/z/d/html/2299.html" rel="external">"NSAIDs: Electrolyte complications"</a>.)</p><p>Occasionally, NSAIDs provide greater pain control and potentially fewer side effects than other medications, particularly among patients with mild reductions in eGFR (ie, &gt;45 mL/min/1.73 m<sup>2</sup>). For such patients, many clinicians will use low doses of NSAIDs after a careful discussion of the potential risks versus benefits of the medication. NSAIDs are best reserved for specific indications of acute, rather than chronic pain, limiting their use to the lowest effective dose and shortest duration [<a href="#rid31">31,32</a>]. All CKD patients who are being chronically treated with NSAIDs should have close monitoring of eGFR (ie, every three months), with discontinuation of NSAIDs if the eGFR declines faster than expected. However, we stress that there is no dose of NSAID that is considered "safe" for individuals with reduced eGFR.</p><p class="headingAnchor" id="H194433508"><span class="h2">Pharmacologic treatment of advanced CKD (eGFR &lt;30 mL/min/1.73 m2)</span><span class="headingEndMark"> — </span>Our pharmacologic approach is adapted from the World Health Organization (WHO) analgesic ladder, which involves a cautious, stepwise approach to prescribing analgesic agents according to pain severity  (<a class="graphic graphic_figure graphicRef126577" href="/z/d/graphic/126577.html" rel="external">figure 1</a>) [<a href="#rid32">32-34</a>]. According to the WHO analgesic ladder, mild pain is treated with nonopioid analgesic agents (tier 1), moderate pain is treated with a weak opioid with or without a nonopioid agent (tier 2), and severe pain is treated with a strong opioid (tier 3)  (<a class="graphic graphic_table graphicRef100573" href="/z/d/graphic/100573.html" rel="external">table 2</a> and <a class="graphic graphic_figure graphicRef126577" href="/z/d/graphic/126577.html" rel="external">figure 1</a>) [<a href="#rid35">35</a>]. The WHO ladder is modified for patients with CKD since many specific agents (such as NSAIDs, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, and <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>) should not be used for individuals with a severely reduced eGFR  (<a class="graphic graphic_table graphicRef100573" href="/z/d/graphic/100573.html" rel="external">table 2</a>) [<a href="#rid32">32,36</a>]. Systematic reviews for nonmalignant chronic pain have supported use of the WHO analgesic ladder approach in the general [<a href="#rid30">30,37-44</a>] and geriatric [<a href="#rid45">45</a>] populations. Most palliative care consensus groups with expertise in caring for CKD patients advocate for this approach [<a href="#rid14">14,29,32,34,46-57</a>].</p><p>We deviate somewhat from the recommendations of the WHO; specifically, we do not use a weak opioid prior to a strong opioid, due to lack of clear advantages with this approach. The weak opioids <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a> and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> have a variable response among patients with advanced CKD, with an unpredictable risk of fatal overdosing with trivial doses or a poor analgesic effect after administration of standard doses [<a href="#rid32">32</a>]. In addition, weak opioids have a similar rate of dose-dependent adverse effects as low-dose strong opioids. There is no evidence that weak opioids have a lower addiction potential compared with low-dose strong opioids. Instead, we favor treatment with a strong opioid initiated at a very low dose with slow titration to desired effect, especially among patients with an eGFR of &lt;30 mL/min/1.73 m<sup>2</sup> [<a href="#rid32">32</a>]. (See <a class="local">'Drugs that should be avoided'</a> below.)</p><p>However, no good studies have examined the effect of treatment algorithms on clinically important outcomes such as pain, overall symptom burden, and quality of life of patients with CKD [<a href="#rid11">11,33</a>].</p><p class="headingAnchor" id="H194433521"><span class="h3">Principles for dosing and administration</span><span class="headingEndMark"> — </span>The general principles of the pharmacologic treatment of pain are the same for patients with advanced CKD as for the general population.</p><p>These include the following principles  (<a class="graphic graphic_table graphicRef100572" href="/z/d/graphic/100572.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>By mouth </strong>– The safest route of administration is oral. However, consideration should also be given to effectiveness, patient comfort, and patient control. For example, if ingestion or absorption of the medication is uncertain, analgesia needs to be given by an alternative route such as transdermal, subcutaneous, or rectal routes. Although hemodialysis patients have easy intravenous access, intravenous administration should be avoided as the route of administration of analgesic agents for chronic pain to optimize safety and minimize the risk of addiction and abuse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>By the clock</strong> – Analgesics given for moderate to severe pain are given on a fixed-dose schedule around the clock and not only on an "as needed" or "prn" basis. This allows for more consistent pain relief. Patients given scheduled analgesics are more comfortable and use less medication overall. Some patients with mild pain may achieve adequate pain relief with analgesic dosing posthemodialysis only. An example is CKD patients with mild neuropathic pain, which may be adequately controlled with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> postdialysis. (See <a class="local">'Neuropathic pain'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>By the ladder</strong> – A stepwise approach is recommended, in which medications are added sequentially. For CKD patients, it is important to select analgesic agents carefully, depending on the eGFR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For the individual</strong> – There is a great deal of interpatient variability in the response to analgesic agents. The maximal dose varies by patient and is identified by the amount needed to relieve the pain without producing intolerable side effects. Since there are no studies on the long-term use of analgesics in patients with CKD, careful attention must be paid to issues of efficacy and safety, and close monitoring is essential.</p><p></p><p>By using this approach, pain can be controlled safely in most patients with advanced CKD and those on dialysis.</p><p class="headingAnchor" id="H194433578"><span class="h3">Drug selection</span><span class="headingEndMark"> — </span>The analgesic choice for individual patients with advanced CKD depends on at least three variables:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The nature of the pain </strong>– For all patients, the choice of analgesic agent for individual patients depends in part on the nature of the pain. Pain is generally classified as either nociceptive or neuropathic. Nociceptive pain is usually due to tissue injury (see <a class="local">'Nociceptive pain'</a> below). Neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system (see <a class="local">'Neuropathic pain'</a> below). Among patients with advanced CKD, the pain is often mixed nociceptive/neuropathic in nature. (See <a class="local">'Mixed nociceptive and neuropathic pain'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The severity of pain </strong>–<strong> </strong>Patients who present with severe pain may require the initiation of stronger agents at the outset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The severity of kidney dysfunction</strong> – Many analgesic agents should have dose reductions or should not be used among individuals with advanced CKD. This is because the pharmacokinetics and pharmacodynamics of many analgesics and most opioids are altered among such patients, and the risk of toxicity from accumulation of renally excreted drugs and their metabolites is high. (See <a class="local">'Drugs that should be avoided'</a> below.)</p><p></p><p>The optimal analgesic agents for CKD patients are indicated in the table  (<a class="graphic graphic_table graphicRef100573" href="/z/d/graphic/100573.html" rel="external">table 2</a>). Suggested dose reductions are based on both clinical experience and available data. Pharmacokinetic data on analgesic medications in the context of advanced CKD may differ from that in the general population  (<a class="graphic graphic_table graphicRef103959" href="/z/d/graphic/103959.html" rel="external">table 4</a>).</p><p>However, the pharmacokinetic and pharmacodynamic data of analgesics in CKD remain limited, and the level of evidence for use of individual analgesics varies considerably. Most pharmacokinetic studies have not been designed to evaluate efficacy and safety and are typically small, single-dose studies or studies over very short periods of time of patients with varying degrees of kidney function. Only a few studies have provided information regarding clinically relevant outcomes such as analgesic effect or adverse effects.</p><p class="headingAnchor" id="H194433596"><span class="h3">Specific pain syndromes</span></p><p class="headingAnchor" id="H1838178070"><span class="h4">Nociceptive pain</span><span class="headingEndMark"> — </span>Causes of nociceptive pain common to patients with advanced CKD include (but are not limited to) osteoarthritis, renal osteodystrophy, dialysis-related amyloid arthropathy, and kidney or liver capsule distension from autosomal dominant polycystic kidney disease (ADPKD). All can cause mild, moderate, or severe pain. Below is presented an approach to mild, moderate, and severe nociceptive pain, based upon the WHO analgesic ladder and modified or reduced eGFR  (<a class="graphic graphic_algorithm graphicRef104061" href="/z/d/graphic/104061.html" rel="external">algorithm 1</a>).</p><p></p><p class="headingAnchor" id="H513530335"><span class="h5">Acetaminophen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a>, prescribed in standard doses, is the first-line analgesic for patients with advanced CKD who have nociceptive pain. Acetaminophen is extensively metabolized in the liver, and only 2 to 5 percent of the parent drug is excreted unchanged in the urine. Acetaminophen elimination is not significantly reduced among patients with decreased eGFR [<a href="#rid58">58</a>]. Cumulative doses of acetaminophen likely do not affect CKD progression [<a href="#rid59">59</a>]. Thus, in the presence of pain, it is relatively safe to give up to a full dose of acetaminophen (ie, a maximum of 4 g daily) to patients with advanced CKD.</p><p class="headingAnchor" id="H513530352"><span class="h5">Opioids</span><span class="headingEndMark"> — </span>For patients who do not respond to <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> alone, we treat with acetaminophen plus a low dose of a strong opioid. Preferred opioids include <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>. We usually start with hydromorphone at 0.5 to 1 mg orally every four to six hours. We do not use <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>/pethidine, or propoxyphene among patients with advanced CKD [<a href="#rid32">32</a>]. <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">Oxycodone</a> or <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a> may be used among patients with CKD but these agents are considered second-line compared with the other opioids discussed above. (See <a class="local">'Drugs that should be avoided'</a> below.)</p><p>The choice of specific agent is generally determined by drug metabolism and availability, clinician comfort and experience with particular agents, and patient preference. As an example, patients may prefer a drug such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>, which is administered via a transdermal route, rather than oral preparations. Side effects such as sedation may also influence the selection of specific agent.</p><p>Opioids should be used with caution among patients with advanced CKD since such patients are at higher risk for toxic side effects compared with patients with normal kidney function. There is a poor understanding of the pharmacokinetics and pharmacodynamics of opioids among patients with severely reduced eGFR. In view of the potential for severe toxicity, normal-release (short-acting), not modified-release (long-acting), preparations are preferred when available  (<a class="graphic graphic_table graphicRef100573" href="/z/d/graphic/100573.html" rel="external">table 2</a>).</p><p>Oral or transdermal agents, rather than parenteral routes, should be used. Patients should be evaluated closely for evidence of benefit and/or toxicity. The onset of adverse side effects should trigger a reassessment of analgesic strategy and choice of opioid.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a><strong> </strong>– Hydromorphone appears to be better tolerated than <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> when immediate-release preparations are used for pain relief [<a href="#rid60">60</a>]. One study that examined the pharmacokinetics and pharmacodynamics and efficacy of hydromorphone among 12 anuric hemodialysis patients found that hydromorphone use resulted in greater than a 65 percent reduction in pain over dosing intervals, with no clinically significant opioid toxicity [<a href="#rid61">61</a>]. Furthermore, hydromorphone did not accumulate in these patients over a mean duration of nine months.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> should be used with caution among all CKD patients, with close observation for side effects. Hydromorphone has a high potential for respiratory depression and addiction.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> is metabolized primarily in the liver to conjugates, hydromorphone-3-glucuronide (H3G), which are excreted in the urine and accumulate in patients with reduced eGFR [<a href="#rid62">62</a>]. Case reports have suggested that the accumulation of H3G conjugate may lead to myoclonus and delirium among patients with severely reduced eGFR [<a href="#rid63">63</a>]. These patients were taking higher doses of hydromorphone than is common in routine practice (equivalent to approximately 3000 mg and 500 to 1000 mg oral <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> per 24 hours, respectively).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">Hydromorphone</a> may not be as well tolerated among patients with severely reduced eGFR (ie, &lt;10 mL/min/1.73 m<sup>2</sup>), either during the final days of life following withdrawal from dialysis or if being managed conservatively without dialysis. In one study of anuric hemodialysis patients, H3G accumulated between dialysis treatments but appeared to be removed effectively during hemodialysis [<a href="#rid61">61</a>]. Among such patients, the clinician should be especially vigilant for toxic side effects. For such patients who develop side effects, other opioids (such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>) may be preferred. Fentanyl is particularly effective among patients who have withdrawn from dialysis in the last days of life since it is transdermally administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a><strong> </strong>– Methadone may be particularly useful for the management of severe chronic pain in patients with advanced CKD. It is excreted mainly in the feces, although approximately 20 percent is excreted unchanged in the urine [<a href="#rid64">64</a>]. In anuric patients, it is excreted exclusively in feces, with no accumulation in plasma. The parent drug and metabolites do not seem to be removed substantially by hemodialysis, so supplemental methadone is not required postdialysis treatment [<a href="#rid65">65,66</a>]. These factors would suggest that methadone may be a safe, effective analgesic for use in patients with advanced CKD by those familiar with its use as careful monitoring is essential, including monitoring for prolongation of the QT interval [<a href="#rid66">66</a>]. In addition, it may be more effective for neuropathic pain than other opioids because of its activity against the N-methyl-D-aspartate (NMDA) receptor antagonism. (See <a class="local">'Neuropathic pain'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a><strong> </strong>– Fentanyl is rapidly metabolized in the liver, with only 5 to 10 percent excreted unchanged in the urine [<a href="#rid67">67</a>]. Its metabolites are considered to be inactive. There does not appear to be any clinically significant accumulation of fentanyl when administered to patients with advanced CKD [<a href="#rid68">68-70</a>]. Similarly, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> is extensively metabolized in the liver to inactive compounds, and its pharmacodynamics and pharmacokinetics in advanced CKD appear relatively unchanged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">Buprenorphine</a><strong> </strong>– Buprenorphine is an effective, long-acting opioid analgesic with an apparent ceiling effect on respiration. It can be administered sublingually or via a transdermal patch. Buprenorphine is a particularly useful analgesic for patients with severely reduced eGFR. Buprenorphine is completely metabolized by the liver, with little unchanged drug found in the urine [<a href="#rid71">71</a>]. Its two major metabolites, buprenorphine-3-glucuronide (B3G) and norbuprenorphine, are primarily excreted via the fecal route, and only 10 to 30 percent of these are excreted in the urine [<a href="#rid72">72</a>]. B3G is inactive, with no analgesic properties, whereas norbuprenorphine has an analgesic effect without the ability to cross the blood-brain barrier and produce toxic neurological side effects [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H1239487165"><span class="h4">Neuropathic pain</span><span class="headingEndMark"> — </span>Common examples of neuropathic pain among patients with advanced CKD include, but are not limited to, diabetic neuropathy, phantom limb pain, and carpel tunnel syndrome. Below is our pharmacologic approach to neuropathic pain, which uses adjuvant therapies such as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> as first-line agents  (<a class="graphic graphic_algorithm graphicRef104062" href="/z/d/graphic/104062.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H513530890"><span class="h5">Gabapentin and pregabalin</span><span class="headingEndMark"> — </span>We treat patients with chronic neuropathic pain with antiseizure medications, including <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. We<em> </em>usually use gabapentin because it is generally the less expensive agent; efficacy and toxicity profiles appear to be similar.</p><p><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is an analog of the neurotransmitter gamma-aminobutyric acid (GABA). Gabapentin is cleared by the kidney, and elimination is markedly reduced in patients with low GFR [<a href="#rid74">74</a>]. As a result, patients with advanced CKD are at an increased risk for side effects such as neurotoxicity and acute kidney injury secondary to rhabdomyolysis [<a href="#rid75">75,76</a>]. Doses should be reduced based on eGFR  (<a class="graphic graphic_table graphicRef103959" href="/z/d/graphic/103959.html" rel="external">table 4</a>). In addition, among older patients or those with only mild neuropathic pain, it is reasonable to start at an even lower dose than permissible by eGFR (eg, 100 mg postdialysis in hemodialysis patients and 100 mg every second night in nondialysis CKD patients with eGFR &lt;15 mL/min/1.73 m<sup>2</sup> who are not on dialysis).</p><p><a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">Pregabalin</a> is also an antiseizure medication that is used to treat refractory neuropathic pain. There have been case reports of neurotoxicity when using pregabalin in CKD patients [<a href="#rid77">77</a>]. Caution must be used and appropriate dose reduction applied  (<a class="graphic graphic_table graphicRef103959" href="/z/d/graphic/103959.html" rel="external">table 4</a>). Among patients with eGFR &lt;15 mL/min/1.73 m<sup>2</sup> who have mild or moderate pain, pregabalin may be effective at doses as low as 25 mg after each dialysis session or 25 mg every second night among patients with eGFR &lt;15 mL/min/1.73 m<sup>2</sup> who are not on dialysis.</p><p>Among patients with severely reduced GFR, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> may have a beneficial effect on other common symptoms among patients with advanced CKD, including pruritus, restless legs syndrome, and poor sleep.</p><p class="headingAnchor" id="H513530905"><span class="h5">Tricyclic antidepressants</span><span class="headingEndMark"> — </span>For patients with neuropathic pain that is unrelieved by the maximum safe dose of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, we switch to a tricyclic antidepressant (TCA). Although TCAs are considered first line for the pharmacologic treatment of neuropathic pain in patients with normal kidney function, we only use TCAs among patients with advanced CKD if gabapentin or pregabalin is not effective. This is because side effects of TCAs are more common among CKD patients. Side effects include dry mouth, orthostatic hypotension, and somnolence due to anticholinergic, histaminergic, and adrenergic activity. TCA-induced tachyarrhythmias are also a concern among CKD patients, given the high burden of cardiovascular disease in CKD. For these reasons, TCAs are considered second-line therapy for neuropathic pain in advanced CKD.</p><p><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> has been the most widely studied TCA in chronic pain [<a href="#rid78">78,79</a>], although a number of others, including <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">doxepin</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>, and <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, also have been used with success.</p><p>We generally start <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> at 10 mg daily. It can take up to six weeks, including two weeks at the highest dose tolerated, for an adequate trial of treatment with TCA, although the onset of analgesia may be after one week [<a href="#rid80">80,81</a>].</p><p>TCAs (mainly those with greater anticholinergic effects) are relatively contraindicated in patients with severe cardiac disease, particularly conduction disturbances.</p><p><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> is a tricyclic compound chemically related to TCAs. It is used for treatment of seizure disorders and as a mood stabilizer. Carbamazepine may be as effective as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> for treating neuropathic pain with fewer adverse effects. Unlike gabapentin and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, it requires no dose adjustment in patients with advanced CKD. We generally start carbamazepine at 100 mg once or twice daily and slowly increase the dose by 100 mg per day to a maximum of 1200 mg per day.</p><p>For patients with neuropathic pain who are unresponsive to <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, TCAs, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, we add traditional analgesics in a stepwise manner, starting with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. (See <a class="local">'Acetaminophen'</a> above.)</p><p>For patients who do not respond to adding <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, an opioid may be added to acetaminophen. (See <a class="local">'Opioids'</a> above.)</p><p><a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">Methadone</a> may be effective for severe neuropathic pain because of its activity against the NMDA receptor antagonism.</p><p>We do not use <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>/pethidine, or propoxyphene among patients with advanced CKD. <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">Oxycodone</a> may be used among patients with advanced CKD but is considered a second-line agent compared with other opioids discussed above. (See <a class="local">'Drugs that should be avoided'</a> below.)</p><p class="headingAnchor" id="H1838178192"><span class="h4">Mixed nociceptive and neuropathic pain</span><span class="headingEndMark"> — </span>Ischemic pain is usually mixed nociceptive and neuropathic. Among patients with advanced CKD, this commonly includes pain from peripheral vascular disease, calciphylaxis, and vascular steal syndrome.</p><p>We treat patients with mixed nociceptive and neuropathic pain with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> (or another adjuvant agent)  (<a class="graphic graphic_algorithm graphicRef104063" href="/z/d/graphic/104063.html" rel="external">algorithm 3</a>). We titrate the dose of gabapentin or pregabalin as required, treating the neuropathic component of the pain before adding other analgesics. For patients who do not respond to acetaminophen plus one of these two drugs, we add an opioid. As noted above, tier 2 agents on the WHO analgesic ladder for the non-CKD population include weak opioids such as <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> and non-opioids such as <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>. However, there is no good weak opioid for patients with advanced CKD. Codeine and tramadol should not be used among patients with advanced CKD. (See <a class="local">'Opioids'</a> above.)</p><p>Thus, for CKD patients with significantly reduced eGFR, most clinicians add a low dose of a strong opioid. (See <a class="local">'Opioids'</a> above.)</p><p>The preferred opioid for mixed nociceptive/neuropathic pain is <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>. Methadone may be effective for severe neuropathic pain because of its activity against the NMDA receptor antagonism.</p><p>We generally do not use NSAIDs, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, propoxyphene, or pethidine among patients with advanced CKD for the treatment of chronic pain. (See <a class="local">'Drugs that should be avoided'</a> below.)</p><p class="headingAnchor" id="H982738882"><span class="h1">DRUGS THAT SHOULD BE AVOIDED</span><span class="headingEndMark"> — </span>We generally do not use nonsteroidal antiinflammatory agents (NSAIDs), <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, dextropropoxyphene, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>/pethidine, or propoxyphene among patients with advanced CKD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal antiinflammatory agents </strong>– NSAIDs may cause an acute reduction in glomerular filtration rate (GFR), sodium and water retention, hypertension, and hyperkalemia and potentially contribute to the progression of CKD (see  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury", section on 'Mechanism of acute kidney injury'</a> and  <a class="medical medical_review" href="/z/d/html/7176.html" rel="external">"Epidemiology and pathogenesis of analgesic-related chronic kidney disease", section on 'Nonsteroidal antiinflammatory drugs'</a> and  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury", section on 'Risk of chronic kidney disease'</a>).</p><p></p><p class="bulletIndent1">NSAIDs also compromise the gastrointestinal mucosa, inhibit platelet function, and are associated with increased risk of cardiovascular morbidity and mortality. All of these potential adverse effects have serious implications for patients with advanced CKD, who are already at high risk for gastrointestinal bleeding and cardiovascular incidents. We avoid NSAIDs, if possible, among patients with estimated GFR (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup>, especially in older adults &gt;75 years.</p><p></p><p class="bulletIndent1">When applied topically, NSAIDs do not appear to be associated with serious side effects. Where pain is present in joints or nonulcerated skin, this may be a useful alternative to oral administration for patients with advanced CKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">Morphine</a><strong> </strong>– We do not use morphine for patients with advanced CKD, although it is considered by many to be the drug of choice for the treatment of severe pain in patients with normal kidney function. Only a small percentage is excreted unchanged in the urine (5 to 10 percent of the dose). The active metabolites, however, accumulate rapidly in patients with GFR &lt;30 mL/min/1.73 m<sup>2</sup> [<a href="#rid82">82-87</a>], potentially causing life-threatening or fatal respiratory depression, and chronic use is associated with significant toxicity. Alternative strong opioids such as <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">alfentanil</a> and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, and <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> are generally more appropriate, especially for patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>. In resource-limited settings where it is the only strong opioid available, morphine should be initiated at very low doses with prolonged intervals (such as every 12 hours) to determine effect before slowly titrating.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">Codeine</a><strong> </strong>– Codeine is metabolized in the liver by the enzyme CYP2D6 to its active metabolite <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, which provides the analgesic effect. Morphine is renally excreted and accumulates in patients with kidney failure [<a href="#rid88">88-90</a>]. The percentage conversion of codeine to morphine in individual patients is highly variable due to the genetic polymorphism of the <em>CYP2D6 </em>gene. Such variable conversion to morphine can result in life-threatening or fatal respiratory depression due to high plasma levels of morphine, even with trivial doses in some and poor analgesic response in others with standard or higher doses [<a href="#rid32">32</a>]. There have been several case reports of prolonged narcosis in patients with CKD following ingestion of codeine, mostly among patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> [<a href="#rid90">90,91</a>]. For this reason, codeine should be avoided among patients with advanced kidney disease, if possible, even though some CKD patients are able to tolerate regular doses of codeine for a prolonged period without experiencing toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">Tramadol</a> –<strong> </strong>Tramadol is metabolized in the liver by the enzyme CYP2D6 with unpredictable bioavailability due to the genetic polymorphism of the <em>CYP2D6 </em>gene. Ninety percent of tramadol and its metabolites are excreted in the urine [<a href="#rid92">92</a>]. Even low doses of tramadol among patients with advanced CKD may cause significant side effects, including central nervous system depression. In addition, serotonin syndrome, a potentially life-threatening condition, may occur with the concurrent use of tramadol and drugs such as antidepressants, which alter the metabolism of tramadol. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dextropropoxyphene </strong>– Dextropropoxyphene is an opioid for mild to moderate pain, usually prescribed in combination with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Dextropropoxyphene is not available in North America, New Zealand, or in European Union countries because of a high fatality risk related to overdose. However, it appears to be available in Asia, and South America. Dextropropoxyphene is contraindicated in patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>. Decreased elimination of dextropropoxyphene and its major pharmacologically active metabolite, norpropoxyphene, has been reported in such patients [<a href="#rid93">93</a>], and its use has been associated with central nervous system (CNS) toxicity, respiratory depression, and cardiotoxicity [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">Oxycodone</a><strong> </strong>–<strong> </strong>We avoid use of<strong> </strong>oxycodone among patients with advanced CKD, whenever possible, due to the risk of respiratory depression [<a href="#rid95">95</a>]. Oxycodone may be used among patients with CKD as a second-line agent after <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> has been attempted. Oxycodone is eliminated mainly by metabolism in the liver to noroxycodone and <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, both of which were shown to accumulate in patients with advanced CKD [<a href="#rid96">96</a>]. Less than 10 percent of oxycodone is excreted unchanged in the urine [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">Meperidine</a><strong>/pethidine</strong> – Meperidine or pethidine is contraindicated in all patients with CKD. Meperidine/pethidine is metabolized in the liver mainly to active metabolites with proconvulsive activity, which accumulate in patients with kidney impairment [<a href="#rid98">98</a>].</p><p></p><p class="headingAnchor" id="H694041092"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H1838178795"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Pain is a common and distressing symptom among patients with chronic kidney disease (CKD). Many analgesics that are typically used in the non-CKD population should not be used among patients with advanced CKD (ie, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>; including those on dialysis). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of pain</strong> – Both dialysis and nondialysis CKD patients should be routinely screened for pain. We screen patients for pain using the Edmonton Symptom Assessment System Revised: Renal (ESAS-r:Renal)  (<a class="graphic graphic_form graphicRef104715" href="/z/d/graphic/104715.html" rel="external">form 1</a>). We screen hemodialysis patients monthly and home dialysis patients and predialysis CKD patients quarterly. (See <a class="local">'Assessment of pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic treatment</strong> – As for the general adult population, treatment options for chronic pain include pharmacologic and nonpharmacologic approaches. Nonpharmacologic modalities are first-line for the treatment of chronic pain in patients with CKD and are generally the same among CKD patients as in the general population. Some patients may be too frail to benefit fully from physical interventions. Behavioral approaches may be challenging for some CKD patients. (See <a class="local">'Treatment overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nociceptive pain</strong> – Nociceptive pain is usually due to tissue injury. Causes of nociceptive pain common to patients with advanced CKD include (but are not limited to) osteoarthritis, renal osteodystrophy, dialysis-related amyloid arthropathy, and kidney or liver capsule distension from autosomal dominant polycystic kidney disease (ADPKD). We suggest the following approach, which is based upon clinical experience rather than published data  (<a class="graphic graphic_algorithm graphicRef104061" href="/z/d/graphic/104061.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We initiate treatment with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. (See <a class="local">'Acetaminophen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who do not respond to <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> alone, a low dose of a strong opioid may be added to acetaminophen. There is no good weak opioid for patients with advanced CKD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preferred opioids include <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, or <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>. (See <a class="local">'Opioids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathic pain</strong> – Neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system. Common examples of neuropathic pain among patients with advanced CKD include diabetic neuropathy, phantom limb pain, and carpel tunnel syndrome. We suggest the following approach, which is based upon clinical experience and expert opinion rather than well-designed clinical trials  (<a class="graphic graphic_algorithm graphicRef104062" href="/z/d/graphic/104062.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent1">We initiate treatment with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> and then switch to a tricyclic antidepressant (TCA) if the gabapentin or pregabalin are not effective. If TCAs are ineffective, we add analgesics as described above. (See <a class="local">'Neuropathic pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed nociceptive/neuropathic pain</strong> – Mixed nociceptive/neuropathic pain is common among patients with advanced CKD and is most often caused by ischemia. We suggest the following approach, which is based upon clinical experience rather than published data  (<a class="graphic graphic_algorithm graphicRef104063" href="/z/d/graphic/104063.html" rel="external">algorithm 3</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Mixed nociceptive and neuropathic pain'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We treat patients with mixed nociceptive and neuropathic pain with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who do not respond to <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> plus <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>/<a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, we add an opioid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The preferred opioid for mixed nociceptive/neuropathic pain is <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that should be avoided</strong> – We generally do not use nonsteroidal antiinflammatory agents (NSAIDs) among patients with CKD. We do not use <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>/pethidine, or propoxyphene among patients with advanced CKD. (See <a class="local">'Pharmacologic treatment of mild to moderate CKD (eGFR ≥30 mL/min/1.73 m2)'</a> above and <a class="local">'Drugs that should be avoided'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davison SN, Rathwell S, Ghosh S, et al. The Prevalence and Severity of Chronic Pain in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis 2021; 8:2054358121993995.</a></li><li><a class="nounderline abstract_t">Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 2006; 69:1621.</a></li><li><a class="nounderline abstract_t">Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 2006; 21:3189.</a></li><li><a class="nounderline abstract_t">Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage 2010; 39:477.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Emont SL, Newmann JM, et al. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 2003; 42:713.</a></li><li><a class="nounderline abstract_t">Leinau L, Murphy TE, Bradley E, Fried T. Relationship between conditions addressed by hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life. Clin J Am Soc Nephrol 2009; 4:572.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Carmody SS, Bruns FJ, et al. Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients. Nephrol Dial Transplant 2003; 18:1345.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005; 16:2487.</a></li><li><a class="nounderline abstract_t">Cohen SD, Patel SS, Khetpal P, et al. Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007; 2:919.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Mor MK, Sevick MA, et al. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol 2014; 9:1594.</a></li><li><a class="nounderline abstract_t">Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial 2014; 27:188.</a></li><li><a class="nounderline abstract_t">Zelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic Pain and High-impact Chronic Pain Among U.S. Adults, 2019. NCHS Data Brief 2020; :1.</a></li><li><a class="nounderline abstract_t">Pham PC, Dewar K, Hashmi S, et al. Pain prevalence in patients with chronic kidney disease. Clin Nephrol 2010; 73:294.</a></li><li><a class="nounderline abstract_t">Davison SN. Chronic pain in end-stage renal disease. Adv Chronic Kidney Dis 2005; 12:326.</a></li><li><a class="nounderline abstract_t">Gamondi C, Galli N, Schönholzer C, et al. Frequency and severity of pain and symptom distress among patients with chronic kidney disease receiving dialysis. Swiss Med Wkly 2013; 143:w13750.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007; 2:960.</a></li><li><a class="nounderline abstract_t">Claxton RN, Blackhall L, Weisbord SD, Holley JL. Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage 2010; 39:211.</a></li><li><a class="nounderline abstract_t">Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract 2009; 111:c74.</a></li><li><a class="nounderline abstract_t">Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care 1999; 8:219.</a></li><li><a class="nounderline abstract_t">Walke LM, Byers AL, McCorkle R, Fried TR. Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manage 2006; 31:31.</a></li><li><a class="nounderline abstract_t">Chiou CP. Development and psychometric assessment of the physical symptom distress scale. J Pain Symptom Manage 1998; 16:87.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Fried LF, Arnold RM, et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 2004; 27:226.</a></li><li><a class="nounderline abstract_t">Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1:277.</a></li><li><a class="nounderline abstract_t">Joshi VD, Mooppil N, Lim JF. Validation of the kidney disease quality of life-short form: a cross-sectional study of a dialysis-targeted health measure in Singapore. BMC Nephrol 2010; 11:36.</a></li><li><a class="nounderline abstract_t">Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire. Am J Kidney Dis 2001; 37:11.</a></li><li class="breakAll">Davison SN. Edmonton Symptom Assessment System Revised Renal (ESAS-r: Renal). Available at: https://www.ckmcare.com/Resources/Details/62 https://www.ckmcare.com/Resources/Details/62 (Accessed on September 22, 2021).</li><li><a class="nounderline abstract_t">Abbey J, Piller N, De Bellis A, et al. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs 2004; 10:6.</a></li><li><a class="nounderline abstract_t">Noordzij M, Boeschoten EW, Bos WJ, et al. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol Dial Transplant 2007; 22:2944.</a></li><li><a class="nounderline abstract_t">Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 2003; 42:1239.</a></li><li class="breakAll">Institute for Clinical Systems Improvement. Health Care Guideline: Pain, Assessment, Non-Opioid Treatment Approaches and Opioid Management. Eighth edition. 2017. https://www.icsi.org/guideline/pain/ (Accessed on September 22, 2021).</li><li><a class="nounderline abstract_t">Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis 2018; 9:143.</a></li><li><a class="nounderline abstract_t">Davison SN. Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure. Clin J Am Soc Nephrol 2019; 14:917.</a></li><li><a class="nounderline abstract_t">Barakzoy AS, Moss AH. Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 2006; 17:3198.</a></li><li class="breakAll">Davison SN, Chambers EJ, Ferro CJ. Management of pain in renal failure. In: Supportive Care for the Renal Patient, 2nd ed., Chambers EJ, Brown E, Germain M (Eds), Oxford University Press, New York 2010. p.139.</li><li class="breakAll">World Health Organization. Cancer pain releif. World Health Organization; Geneva, 1990.</li><li><a class="nounderline abstract_t">Ishida JH, McCulloch CE, Steinman MA, et al. Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. Clin J Am Soc Nephrol 2018; 13:746.</a></li><li class="breakAll">Acute pain management: Scientific evidence. In: Australian and New Zealand College of Anaesthetic (ANZCA) and Faculty of Pain Medicine, 3rd ed., Macintyre P, Scott DA, Schug SA, et al (Eds), 2010.</li><li><a class="nounderline abstract_t">Horber FF, Guentert TW, Weidekamm E, et al. Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharmacol 1986; 29:697.</a></li><li class="breakAll">Daousi C, Nurmikko T. Painful diabetic neuropathy. In: Evidence-Based Chronic Pain Management, Stannard C, Kalso E, Ballantyne J (Eds), BMJ Books, London 2010.</li><li><a class="nounderline abstract_t">Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85:S3.</a></li><li><a class="nounderline abstract_t">Volkow N, Benveniste H, McLellan AT. Use and Misuse of Opioids in Chronic Pain. Annu Rev Med 2018; 69:451.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. Available at: https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf (Accessed on September 22, 2021).</li><li><a class="nounderline abstract_t">Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ 2017; 189:E659.</a></li><li><a class="nounderline abstract_t">Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician 2017; 20:S3.</a></li><li><a class="nounderline abstract_t">Ali A, Arif AW, Bhan C, et al. Managing Chronic Pain in the Elderly: An Overview of the Recent Therapeutic Advancements. Cureus 2018; 10:e3293.</a></li><li><a class="nounderline abstract_t">Davison SN, Ferro CJ. Management of pain in chronic kidney disease. Prog Palliat Care 2009; 17:186.</a></li><li><a class="nounderline abstract_t">Davison SN. The prevalence and management of chronic pain in end-stage renal disease. J Palliat Med 2007; 10:1277.</a></li><li><a class="nounderline abstract_t">Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.</a></li><li><a class="nounderline abstract_t">Harris D. Pain management in patients with renal impairment. Eur J Palliat Care 2008; 15:214.</a></li><li><a class="nounderline abstract_t">Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42:217.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V, Karie S, Fau JB, et al. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005; 6:137.</a></li><li><a class="nounderline abstract_t">Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J 2006; 32:93.</a></li><li><a class="nounderline abstract_t">Murtagh FE, Chai MO, Donohoe P, et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21:5.</a></li><li><a class="nounderline abstract_t">Naylor HK, Raymond CB. Treatment of neuropathic pain in patients with chronic kidney disease. CANNT J 2011; 21:34.</a></li><li><a class="nounderline abstract_t">Young BA, Hynes J, McComb T, Blagg CR. Associations with home hemodialysis modality failure and mortality. Hemodial Int 2004; 8:344.</a></li><li><a class="nounderline abstract_t">Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010; 11:752.</a></li><li><a class="nounderline abstract_t">Pham PC, Toscano E, Pham PM, et al. Pain management in patients with chronic kidney disease. NDT Plus 2009; 2:111.</a></li><li><a class="nounderline abstract_t">Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7:93.</a></li><li><a class="nounderline abstract_t">Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant 2009; 24:1908.</a></li><li><a class="nounderline abstract_t">Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15:26.</a></li><li><a class="nounderline abstract_t">Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008; 4:335.</a></li><li><a class="nounderline abstract_t">Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10:184.</a></li><li><a class="nounderline abstract_t">Fainsinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9:53.</a></li><li><a class="nounderline abstract_t">Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat. J Med Chem 1971; 14:194.</a></li><li><a class="nounderline abstract_t">Perlman R, Giladi H, Brecht K, et al. Intradialytic clearance of opioids: methadone versus hydromorphone. Pain 2013; 154:2794.</a></li><li><a class="nounderline abstract_t">Opdal MS, Arnesen M, Müller LD, et al. Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. Clin Ther 2015; 37:1594.</a></li><li><a class="nounderline abstract_t">McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28:106.</a></li><li><a class="nounderline abstract_t">Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17:746.</a></li><li><a class="nounderline abstract_t">Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 1982; 34:102.</a></li><li><a class="nounderline abstract_t">Mercadante S, Caligara M, Sapio M, et al. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 1997; 13:241.</a></li><li><a class="nounderline abstract_t">Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64:276.</a></li><li><a class="nounderline abstract_t">Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003; 70:S39.</a></li><li><a class="nounderline abstract_t">Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006; 10:743.</a></li><li><a class="nounderline abstract_t">Healy DG, Ingle GT, Brown P. Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure. Mov Disord 2009; 24:2028.</a></li><li><a class="nounderline abstract_t">Torregrosa-de Juan E, Olagüe-Díaz P, Royo-Maicas P, et al. Acute renal failure due to gabapentin. A case report and literature. Nefrologia 2012; 32:130.</a></li><li><a class="nounderline abstract_t">Bassilios N, Launay-Vacher V, Khoury N, et al. Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 2001; 16:2112.</a></li><li><a class="nounderline abstract_t">Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43:277.</a></li><li><a class="nounderline abstract_t">Pilowsky I, Hallett EC, Bassett DL, et al. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982; 14:169.</a></li><li><a class="nounderline abstract_t">Jaeschke R, Adachi J, Guyatt G, et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991; 18:447.</a></li><li><a class="nounderline abstract_t">Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237.</a></li><li><a class="nounderline abstract_t">Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289.</a></li><li><a class="nounderline abstract_t">Säwe J, Odar-Cederlöf I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 1987; 32:377.</a></li><li><a class="nounderline abstract_t">Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62:28.</a></li><li><a class="nounderline abstract_t">Chauvin M, Sandouk P, Scherrmann JM, et al. Morphine pharmacokinetics in renal failure. Anesthesiology 1987; 66:327.</a></li><li><a class="nounderline abstract_t">Osborne R, Joel S, Slevin M. Morphine intoxication in renal failure; the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986; 293:1101.</a></li><li><a class="nounderline abstract_t">Wolff J, Bigler D, Christensen CB, et al. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988; 34:353.</a></li><li><a class="nounderline abstract_t">Hanna MH, D'Costa F, Peat SJ, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70:511.</a></li><li><a class="nounderline abstract_t">Barnes JN, Williams AJ, Tomson MJ, et al. Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J (Clin Res Ed) 1985; 290:740.</a></li><li><a class="nounderline abstract_t">Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43:63.</a></li><li><a class="nounderline abstract_t">Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31:410.</a></li><li><a class="nounderline abstract_t">Barnes JN, Goodwin FJ. Dihydrocodeine narcosis in renal failure. Br Med J (Clin Res Ed) 1983; 286:438.</a></li><li><a class="nounderline abstract_t">Lintz W, Erlaçin S, Frankus E, Uragg H. [Biotransformation of tramadol in man and animal (author's transl)]. Arzneimittelforschung 1981; 31:1932.</a></li><li><a class="nounderline abstract_t">Gibson TP, Giacomini KM, Briggs WA, et al. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 1980; 27:665.</a></li><li><a class="nounderline abstract_t">Nickander RC, Emmerson JL, Hynes MD, et al. Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Hum Toxicol 1984; 3 Suppl:13S.</a></li><li><a class="nounderline abstract_t">Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. South Med J 2007; 100:212.</a></li><li><a class="nounderline abstract_t">Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8:13.</a></li><li><a class="nounderline abstract_t">Pöyhiä R, Seppälä T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33:617.</a></li><li><a class="nounderline abstract_t">Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86:738.</a></li></ol></div><div id="topicVersionRevision">Topic 93774 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33680484" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Prevalence and Severity of Chronic Pain in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672923" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957010" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20303025" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520621" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261828" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Relationship between conditions addressed by hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808172" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975996" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702733" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pain, sleep disturbance, and quality of life in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081360" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24517512" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pain in chronic kidney disease: a scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33151145" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic Pain and High-impact Chronic Pain Among U.S. Adults, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20353737" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pain prevalence in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010647" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic pain in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23443906" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Frequency and severity of pain and symptom distress among patients with chronic kidney disease receiving dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702730" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renal provider recognition of symptoms in patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19963337" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Undertreatment of symptoms in patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088482" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10847883" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442480" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Symptom assessment in community-dwelling older adults with advanced chronic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737099" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Development and psychometric assessment of the physical symptom distress scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15010101" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1235985" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The McGill Pain Questionnaire: major properties and scoring methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172008" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Validation of the kidney disease quality of life-short form: a cross-sectional study of a dialysis-targeted health measure in Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136162" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136162" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966439" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597087" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655196" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pain in hemodialysis patients: prevalence, cause, severity, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655196" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pain in hemodialysis patients: prevalence, cause, severity, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29392089" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30833302" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988057" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988057" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988057" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674340" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674340" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3709612" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics of tenoxicam in patients with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3709612" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacokinetics of tenoxicam in patients with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194146" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029586" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use and Misuse of Opioids in Chronic Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029586" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use and Misuse of Opioids in Chronic Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483845" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Guideline for opioid therapy and chronic noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28226332" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30443463" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Managing Chronic Pain in the Elderly: An Overview of the Recent Therapeutic Advancements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Management of pain in chronic kidney disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095806" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The prevalence and management of chronic pain in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504625" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Opioids in renal failure and dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pain management in patients with renal impairment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900801" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Analgesia in patients with ESRD: a review of available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772907" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16898102" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Symptom management in patients with established renal failure managed without dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17844723" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561014" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of neuropathic pain in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19379440" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Associations with home hemodialysis modality failure and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20041843" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of major analgesics in patients with renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25949305" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pain management in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039926" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical pharmacokinetics of paracetamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155536" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Acetaminophen, aspirin and progression of advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11212464" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192761" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7543126" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hydromorphone metabolite accumulation in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684078" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5552207" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973378" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intradialytic clearance of opioids: methadone versus hydromorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963997" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effects of Hemodialysis on Methadone Pharmacokinetics and QTc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7389247" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intravenous fentanyl kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250552" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fentanyl pharmacokinetics in patients undergoing renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6121867" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136236" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2328175" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738349" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pharmacokinetics of the combination tablet of buprenorphine and naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426877" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19642217" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22294020" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acute renal failure due to gabapentin. A case report and literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572915" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gabapentin neurotoxicity in a chronic haemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638396" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pharmacokinetics of pregabalin in subjects with various degrees of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6757842" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A controlled study of amitriptyline in the treatment of chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1856813" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920770" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pharmacologic management of neuropathic pain: evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213659" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Algorithm for neuropathic pain treatment: an evidence based proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3609116" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Kinetics of morphine in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644963" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826690" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Morphine pharmacokinetics in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3094793" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Morphine intoxication in renal failure; the role of morphine-6-glucuronide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3402521" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Influence of renal function on the elimination of morphine and morphine glucuronides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318321" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Morphine-6-glucuronide disposition in renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918735" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335120" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968655" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pharmacokinetics of opioids in renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6401554" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Dihydrocodeine narcosis in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7198474" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : [Biotransformation of tramadol in man and animal (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7371364" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6090306" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330696" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Oxycodone accumulation in a hemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695073" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389934" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869353" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
